Exchange Traded Concepts LLC Has $6.07 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Exchange Traded Concepts LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 10.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,505 shares of the company’s stock after buying an additional 6,543 shares during the period. Exchange Traded Concepts LLC’s holdings in Novo Nordisk A/S were worth $6,065,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of NVO. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the third quarter valued at $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $42,000. Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the third quarter worth $48,000. Finally, M&R Capital Management Inc. increased its holdings in Novo Nordisk A/S by 260.5% in the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after purchasing an additional 297 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $87.94 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a fifty day simple moving average of $95.62 and a two-hundred day simple moving average of $115.55. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The firm has a market cap of $394.65 billion, a price-to-earnings ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on NVO shares. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.